

February 16, 2023

TAKE/BSE/2022-23

The Manager

Dept. of Corporate Services-Listing

BSE Limited,

P. J. Towers, Dalal Street,

Mumbai - 400001

**Scrip Code: 532890**

TAKE/NSE/2022-23

The Manager-Listing Department

National Stock Exchange of India Limited

Exchange Plaza,

Bandra - Kurla Complex, Bandra (East),

Mumbai - 400051

**Symbol: TAKE**

Dear Sir/ Madam,

**Sub: Newspaper Publication**

Pursuant to Regulations 33 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith, the extract of the Consolidated Unaudited Financial Results for the quarter ended December 31, 2022, published in newspapers, namely, Makkal Kural (Tamil) and Financial Express (English), dated February 15, 2023, and February 16, 2023, respectively.

Kindly take the same on record and acknowledge.

Thanking you.

Yours sincerely,

For TAKE Solutions Limited



**Srinivasan. P**

**Company Secretary**

Encl: As above.





# Tube to drive in electric 3W, truck in March

SAJAN C KUMAR  
Chennai, February 15



Vellayan Subbiah, executive vice-chairman, TII

**TUBE INVESTMENTS OF India** (TII), part of the Murugappa group, will start rolling out its much-awaited electric three-wheeler Montra and an electric truck in March this year. The company's e-tractor will be launched by July through its newly-formed mobility arm - TI Clean Mobility.

Vellayan Subbiah, executive vice-chairman, TII, told analysts that it will start manufacturing of e-three-wheelers and put out the first set of products in March with its current plan and then start selling, increasing volumes from April onwards. He said the e-truck of 55-tonne will follow a similar timeline.

At the launch of e-three wheeler in September last year, the company had said the vehicle's delivery will begin as early as in October at TII's Ambattur facility near Chennai. But it was delayed, and the management of the company now said delivery of the vehicle will

## Moody's retains stable outlook for TCS, Infosys

PRESS TRUST OF INDIA  
New Delhi, February 15

**MOODY'S INVESTORS SERVICE** on Wednesday affirmed the ratings of two major Indian IT services companies, Tata Consultancy Services (TCS) and Infosys.

In two separate statements, Moody's also retained stable outlook for both the companies. Moody's expects Infosys' revenues to climb by around 13% for the financial year ending March 31, 2023, but moderate to around 8% in the next 2024 fiscal.

"Moody's Investors Service has today affirmed the Baa1 local currency issuer rat-

ing of Infosys. The rating outlook remains stable," it said in a release.

The rating affirmation reflects Infosys' position as one of the world's leading IT solutions and services providers with globally diversified, cost-competitive operations that translate into its sustained, strong profitability and robust credit profile, Kaustubh Chaubal, Moody's senior vice-president said.

"Infosys' good corporate governance practices, reflected in its extremely strong balance sheet, large liquidity and net cash position, support its Baa1 rating," Chaubal said. A vast majority of Infosys' workforce is

based in India. As well, the company is exposed to changes in regulations and tax laws in India. Given this exposure, Infosys' rating is constrained at two notches above the rating of its country of domicile and incorporation, India (Baa3 stable), based on Moody's cross-sector methodology.

Moody's observed that a globally diversified operations, demonstrated track record in delivering strong operating results with industry leading profitability, large positive free cash flow generation and minimal reliance on the Indian banking system allow Infosys to be rated two-notches higher than the Indian sovereign.

## Amrutanjan shares fall 8.15% after whistleblower complaint on fraud

SAJAN C KUMAR  
Chennai, February 15

**SHARES OF AMRUTANJAN** Healthcare fell 8.15% on the BSE on Wednesday, a day after it initiated a forensic investigation by Deloitte Touche Tohmatsu India LLP on an anonymous whistleblower complaint alleg-

ing some senior management of "undue enrichment" and "conflict of interest".

The shares of the Chennai headquartered company, popular for its pain relief products, closed at ₹645.35 on BSE, sliding by ₹57.25 or 8.15% from its previous close of ₹702.60. The company received an

anonymous whistleblower complaint alleging lapses by certain senior management employees, including undue enrichment through marketing, advertising and procurement activities, ethical concerns, and conflict of interest, Amrutanjan said in a communication to the BSE.

## Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

Registered Office: No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agrah Extension, Bengaluru-560102, Karnataka, India.

Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

### STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

(Amount in INR crores except per share data)

Particulars	Consolidated						Standalone					
	Quarter ended		Nine Months ended		Year ended		Quarter ended		Nine Months ended		Year ended	
	31-Dec-22 (Unaudited)	30-Sep-22 (Unaudited)	31-Dec-21 (Unaudited)	31-Dec-22 (Unaudited)	31-Dec-21 (Audited)	31-Mar-22 (Unaudited)	31-Dec-22 (Unaudited)	30-Sep-22 (Unaudited)	31-Dec-21 (Unaudited)	31-Dec-22 (Unaudited)	31-Dec-21 (Unaudited)	31-Mar-22 (Audited)
Total Income	3,200.67	2,834.72	2,661.09	8,734.78	7,554.17	10,303.94	409.33	395.73	301.90	1141.82	853.34	1,198.67
Net profit/ (loss) before tax	173.44	70.64	181.34	329.30	387.03	636.85	41.44	56.96	19.34	128.28	27.31	89.96
Net profit/ (loss) after tax	159.03	54.10	168.20	292.90	355.42	601.05	34.58	56.96	19.34	121.42	27.31	90.18
Total Comprehensive Income/ (loss)	191.59	117.29	171.21	466.88	376.60	694.50	34.58	56.96	19.34	121.42	27.31	90.64
Equity Share Capital	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52
Other Equity	-	-	-	-	-	-	3,453.89	-	-	-	-	2,455.69
Earnings per share (Face value of INR 10 each)	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised
Basic	2.80	0.93	2.98	5.11	6.03	10.58	0.70	1.15	0.39	2.44	0.55	1.81
Diluted	2.80	0.93	2.98	5.10	6.02	10.57	0.69	1.14	0.39	2.44	0.55	1.81

\*The unaudited consolidated and standalone financial results of the Company for the quarter and nine months ended December 31, 2022 have been reviewed by the Audit Committee on February 14, 2023 and approved by the Board of Directors at its meeting held on February 14, 2023.

\*The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial statements is made available on the Company's website at [www.asterdmhealthcare.com/investors](http://www.asterdmhealthcare.com/investors) and stock exchange website at BSE <https://www.bseindia.com/> and NSE <https://www.nseindia.com/>.

\*The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.

For Aster DM Healthcare Limited

Sd/-  
Dr. Azad Moopen  
Chairman and Managing Director  
DIN: 00159403

Place: Dubai  
Date: February 14, 2023

## Balmer Lawrie Investments Limited

[A Government of India Enterprise]

Regd. Office: 21, Netaji Subhas Road, Kolkata - 700001 Tel. No. - (033)2222 5227, E-mail: [lahoti.a@balmerlawrie.com](mailto:lahoti.a@balmerlawrie.com)

website: [www.blinv.com](http://www.blinv.com) • CIN : L65999WB2001GOI093759

### EXTRACTS OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED ON DECEMBER 31, 2022

(₹ in Lakhs)

Sl. No.	Particulars	STANDALONE						CONSOLIDATED					
		Quarter Ending December 31, 2022 (Unaudited)	Preceding Quarter Ending September 30, 2022 (Unaudited)	Corresponding 3 months Ending December 31, 2021 (Unaudited)	Year to date Figures for the Current Period Ending December 31, 2022 (Unaudited)	Year to date Figures for the Previous Period Ending December 31, 2021 (Audited)	Previous Period Ended March 31, 2022 (Unaudited)	Quarter Ending December 31, 2022 (Unaudited)	Preceding Quarter Ending September 30, 2022 (Unaudited)	Corresponding 3 months Ending December 31, 2021 (Unaudited)	Year to date Figures for the Current Period Ending December 31, 2022 (Unaudited)	Year to date Figures for the Previous Period Ending December 31, 2021 (Unaudited)	Previous Period Ended March 31, 2022 (Audited)
1	Total Income from Operations	198.22	7034.80	146.63	7371.84	6799.55	6941.83	51925.03	56070.73	51179.63	17375.18	150632.58	210551.19
2	Net Profit/ (Loss) for the period (before Tax, Exceptional and Extraordinary items)	171.57	7007.34	120.61	7292.36	6665.95	6780.31	4710.47	4630.48	3286.55	16110.58	11235.58	18648.80
3	Net Profit/ (Loss) for the period before Tax (after Exceptional and Extraordinary items)	171.57	7007.34	120.61	7292.36	6665.95	6780.31	4710.47	4630.48	3286.55	16110.58	11235.58	18648.80
4	Net Profit/ (Loss) for the period after Tax (after Exceptional and Extraordinary items)	127.47	6971.44	88.61	7182.96	6580.95	6661.70	3689.93	3525.77	2720.89	12837.73	9079.81	13796.39
5	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	127.47	6971.44	88.61	7182.96	6580.95	6661.70	3693.38	3525.49	2725.79	12840.69	9083.23	13035.57
6	Equity Share Capital	2219.73	2219.73	2219.73	2219.73	2219.73	2219.73	2219.73	2219.73	2219.73	2219.73	2219.73	2219.73
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year					13775.78						109428.88	
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations)(In ₹) (not annualised)												
1.	Basic:	0.57	31.41	0.40	32.36	29.65	30.01	11.00	10.24	7.96	37.25	26.38	39.88
2.</td													